I'm LongbridgeAI, I can summarize articles.The EU's Committee for Medicinal Products for Human Use (CHMP) has recommended approving Roche’s Susvimo for treating neovascular age-related macular degeneration. This implant continuously delivers ranibizumab, offering an alternative to frequent injections with clinical data showing comparable vision outcomes and reduced need for supplemental treatments. The recommendation paves the way for a final European Commission decision.
- EU drug regulator CHMP recommended approval of Roche’s Susvimo for neovascular age-related macular degeneration, paving the way for a European Commission decision. * Susvimo uses the Contivue refillable eye implant to continuously deliver ranibizumab, positioned as an alternative to frequent anti-VEGF injections. * Archway, LADDER, Portal data showed vision outcomes comparable to monthly ranibizumab injections; about 95% needed no supplemental anti-VEGF with two refills yearly. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607240615OMX_____CNEWS_EN_GNW1001214281_en) on July 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)